GlobeNewsWire
09 Jul 2026, 12:45 UTC · 2h ago
Amplia Announces Publication of New FAK Inhibitor Patent Application
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
09 Jul 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Amplia Therapeutics has published a new patent application for novel focal adhesion kinase (FAK) inhibitors that could provide protection until 2046. — Expanding IP protection and the chemical variety of drug candidates increases the long-term commercial value and moat of the company's lead assets.
+0.40The company's lead drug, narmafotinib, achieved a 36% response rate (including 5 complete responses) in the ACCENT clinical trial for advanced pancreatic cancer. — Positive clinical trial data for a high-unmet-need indication like pancreatic cancer is a primary driver of biotech valuation.
+0.30The new patent application describes compounds related to narmafotinib that may allow for evaluation across additional medical indications. — Broadening the potential pipeline beyond the current trials increases the total addressable market and partnering opportunities.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced a new patent application that expands its intellectual property portfolio and strengthens its FAK inhibitor program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Barrons
3h ago
